Segall Bryant & Hamill LLC Has $6.99 Million Stock Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Segall Bryant & Hamill LLC lifted its stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 43.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 193,459 shares of the company's stock after acquiring an additional 58,522 shares during the period. Segall Bryant & Hamill LLC owned approximately 0.26% of SpringWorks Therapeutics worth $6,990,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of SWTX. AlphaQuest LLC boosted its holdings in SpringWorks Therapeutics by 70.2% in the 4th quarter. AlphaQuest LLC now owns 1,004 shares of the company's stock valued at $36,000 after purchasing an additional 414 shares during the period. Venturi Wealth Management LLC acquired a new position in shares of SpringWorks Therapeutics during the fourth quarter valued at about $45,000. KBC Group NV lifted its stake in shares of SpringWorks Therapeutics by 59.1% in the fourth quarter. KBC Group NV now owns 2,634 shares of the company's stock valued at $95,000 after buying an additional 978 shares during the period. US Bancorp DE grew its position in SpringWorks Therapeutics by 56.0% during the fourth quarter. US Bancorp DE now owns 4,336 shares of the company's stock worth $157,000 after buying an additional 1,556 shares in the last quarter. Finally, Quantbot Technologies LP bought a new position in SpringWorks Therapeutics during the third quarter valued at about $147,000.

Insiders Place Their Bets

In other SpringWorks Therapeutics news, insider Bhavesh Ashar sold 1,016 shares of the business's stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $61.19, for a total value of $62,169.04. Following the transaction, the insider now owns 62,053 shares of the company's stock, valued at approximately $3,797,023.07. The trade was a 1.61 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Saqib Islam sold 48,000 shares of the firm's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $53.30, for a total value of $2,558,400.00. Following the completion of the sale, the chief executive officer now owns 1,002,502 shares of the company's stock, valued at approximately $53,433,356.60. This trade represents a 4.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 440,766 shares of company stock valued at $24,402,956. 7.61% of the stock is currently owned by insiders.

Remove Ads

SpringWorks Therapeutics Trading Down 6.9 %

SWTX stock traded down $3.28 during trading on Monday, hitting $44.13. The company had a trading volume of 2,411,930 shares, compared to its average volume of 1,302,115. The company has a fifty day moving average price of $48.17 and a two-hundred day moving average price of $39.81. SpringWorks Therapeutics, Inc. has a fifty-two week low of $28.21 and a fifty-two week high of $62.00. The company has a market cap of $3.31 billion, a P/E ratio of -12.68 and a beta of 0.76.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last issued its earnings results on Thursday, February 20th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.38). The firm had revenue of $61.55 million during the quarter, compared to analyst estimates of $60.53 million. SpringWorks Therapeutics had a negative net margin of 134.73% and a negative return on equity of 46.74%. On average, analysts expect that SpringWorks Therapeutics, Inc. will post -2.05 earnings per share for the current year.

Wall Street Analysts Forecast Growth

SWTX has been the subject of a number of research reports. Wedbush reiterated an "outperform" rating and issued a $81.00 price objective on shares of SpringWorks Therapeutics in a research report on Thursday, February 20th. HC Wainwright reaffirmed a "buy" rating and issued a $74.00 target price on shares of SpringWorks Therapeutics in a research report on Friday, February 21st. Evercore ISI lifted their price target on shares of SpringWorks Therapeutics from $60.00 to $65.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 12th. Finally, Guggenheim dropped their price objective on shares of SpringWorks Therapeutics from $80.00 to $78.00 and set a "buy" rating for the company in a research note on Wednesday, January 8th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $73.20.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.